| Literature DB >> 22158866 |
Yasuhiro Maeno1, Qian Li, Kyoungmin Park, Christian Rask-Madsen, Benbo Gao, Motonobu Matsumoto, Yingjie Liu, I-Hsien Wu, Morris F White, Edward P Feener, George L King.
Abstract
The regulation of endothelial function by insulin is consistently abnormal in insulin-resistant states and diabetes. Protein kinase C (PKC) activation has been reported to inhibit insulin signaling selectively in endothelial cells via the insulin receptor substrate/PI3K/Akt pathway to reduce the activation of endothelial nitric-oxide synthase (eNOS). In this study, it was observed that PKC activation differentially inhibited insulin receptor substrate 1/2 (IRS1/2) signaling of insulin's activation of PI3K/eNOS by decreasing only tyrosine phosphorylation of IRS2. In addition, PKC activation, by general activator and specifically by angiotensin II, increased the phosphorylation of p85/PI3K, which decreases its association with IRS1 and activation. Thr-86 of p85/PI3K was identified to be phosphorylated by PKC activation and confirmed to affect IRS1-mediated activation of Akt/eNOS by insulin and VEGF using a deletion mutant of the Thr-86 region of p85/PI3K. Thus, PKC and angiotensin-induced phosphorylation of Thr-86 of p85/PI3K may partially inhibit the activation of PI3K/eNOS by multiple cytokines and contribute to endothelial dysfunction in metabolic disorders.Entities:
Mesh:
Substances:
Year: 2011 PMID: 22158866 PMCID: PMC3281670 DOI: 10.1074/jbc.M111.286591
Source DB: PubMed Journal: J Biol Chem ISSN: 0021-9258 Impact factor: 5.157